OmniActive’s Zenroot Earns USP Seal, Raising the Bar for Ashwagandha

BRIDGEWATER, NJ – August 10, 2026

OmniActive Health Technologies has secured a significant quality milestone for its ashwagandha extract, Zenroot, earning verification from the U.S. Pharmacopeia (USP). This makes Zenroot the only root-only ashwagandha extract with a low 125 mg daily dose to carry the coveted USP Verified seal, a mark of independent quality assurance. The move is a direct response to a burgeoning market grappling with a crisis of confidence, where rapid growth has been shadowed by concerns over ingredient adulteration and inconsistent quality. For investors and brand strategists, this development signals a critical shift in the botanical supplement space, where verifiable quality is becoming the ultimate competitive advantage.

The Trust Deficit in a High-Growth Market

The consumer appetite for ashwagandha, an adaptogenic herb revered in Ayurvedic tradition for its stress-relieving properties, is undeniable. Market projections from Mordor Intelligence forecast the global market to climb from $0.76 billion in 2025 to $1.18 billion by 2030. This expansion is fueled by a wellness-conscious public seeking natural solutions for mood, sleep, and overall well-being. Yet, beneath this impressive growth trajectory lies a persistent and troubling issue: a significant trust deficit rooted in widespread quality control failures.

The core of the problem is adulteration. Industry reports and academic studies have repeatedly flagged the common practice of substituting or diluting authentic ashwagandha root with cheaper, undeclared leaf and stem materials. While both root and leaf contain the active compounds known as withanolides, their phytochemical profiles are vastly different. Traditional use and regulatory standards primarily recognize the root for systemic health benefits, while leaves contain higher levels of withaferin A, a compound that has raised safety concerns regarding potential liver toxicity. Some analyses suggest that up to 80% of commercial products may be adulterated with non-root materials, creating a minefield for manufacturers and a gamble for consumers.

"Ashwagandha continues to gain attention as consumers seek natural solutions to support overall well-being, but category growth and adulterations are also raising the bar for quality and transparency," said Brijesh Shah, Chief Operating Officer at OmniActive. This sentiment captures the central tension in the market: as demand soars, so does the need for unimpeachable quality.

Raising the Bar: The Significance of USP Verification

In this climate of uncertainty, third-party verification becomes more than a rubber stamp; it becomes a foundational pillar of trust. The USP Ingredient Verification Program is among the most rigorous in the industry. It confirms that an ingredient meets stringent criteria for identity (it is what it says it is), purity (it is free from harmful contaminants), and potency (it contains the correct strength of active compounds). Furthermore, it verifies that the ingredient is produced according to FDA-mandated current Good Manufacturing Practices (cGMPs).

"USP is delighted to recognize OmniActive's approval of Zenroot as a USP Verified Dietary Ingredient," noted Emily Rose Britton, PhD, Senior Manager of Market Development for Verification Programs at USP. "This accomplishment demonstrates a commitment to quality, enabling dietary supplement manufacturers to identify OmniActive's Zenroot as a trusted quality ingredient."

For brand manufacturers, this verification de-risks the sourcing process. Instead of navigating a complex and often opaque supply chain, they can select an ingredient with a pre-vetted assurance of quality and consistency. This simplifies supplier qualification, aids regulatory compliance, and provides a powerful differentiator in a crowded marketplace. A spokesperson for OmniActive emphasized the importance of accessible testing standards, stating, "Method transparency is increasingly important for building trust across the supply chain." By using USP-published methods for testing, Zenroot allows for independent verification by laboratories worldwide, reinforcing its commitment to an open and honest standard.

Science and Versatility: The Engine of Innovation

While the USP seal validates the quality of the raw ingredient, OmniActive has layered this with clinical science to demonstrate performance. Two recent peer-reviewed studies published in Advances in Therapy underscore Zenroot's efficacy and unique bioavailability, providing the "why behind the buy" for formulators.

The first study revealed that a single 125 mg dose of Zenroot delivered superior bioavailability compared to two leading commercial extracts at much higher doses (500 mg and 600 mg). This means a greater concentration of the active withanolides reaches the bloodstream, suggesting a higher level of efficiency from a smaller dose. This finding is crucial, as it directly addresses the performance of the ingredient once consumed.

A second 12-week, placebo-controlled clinical trial translated this bioavailability into tangible health benefits. Participants taking just 125 mg of Zenroot daily reported significant reductions in feelings of occasional stress and anxiety, fewer mood fluctuations, and notable improvements in sleep quality compared to the placebo group. These outcomes, achieved at a low dose, not only validate the ingredient's efficacy but also unlock significant formulation potential.

Zenroot's low-dose profile, combined with favorable organoleptic properties, allows brands to break free from the constraints of traditional capsules. The ashwagandha market is rapidly innovating into more consumer-friendly formats like gummies, chews, functional beverages, and ready-to-mix powders—segments that are outpacing the growth of the overall market. Zenroot's versatility makes it an ideal candidate for these applications, where taste, solubility, and a small ingredient footprint are paramount.

A New Competitive Benchmark

By securing USP verification for a low-dose, root-only, and clinically substantiated extract, OmniActive has strategically positioned Zenroot in the competitive landscape. While other well-regarded extracts like KSM-66 (root-only) and Sensoril (root and leaf) have their own extensive clinical backing, Zenroot's combination of USP verification, superior bioavailability at a low 125 mg dose, and a strict root-only promise creates a unique and compelling value proposition.

The focus on a root-only source directly addresses the industry's adulteration concerns and aligns with the most stringent quality standards. The USP seal provides an unambiguous, independent mark of quality that resonates with discerning manufacturers and, ultimately, consumers. In the rapidly evolving 2026 wellness market, where transparency is no longer a luxury but a core expectation, this multi-pronged approach of verifiable quality, proven science, and formulation flexibility sets a new benchmark. This development will likely compel competitors to bolster their own quality assurances and pushes the entire category toward a higher standard, a clear win for brands and consumers seeking effective and trustworthy botanical solutions.